/CNW/ - Soricimed Biopharma Inc., ("Soricimed" or "the Company"), a clinical stage company focused on the development and commercialization of first-in-class.
Share this article
Share this article
MONCTON, NB, Dec. 17, 2020 /CNW/ - Soricimed Biopharma Inc., ( Soricimed ), a privately-held, science-based, clinical stage company focused on the development and commercialization of first-in-class targeted cancer therapeutics, today announced that it will investigate the potential therapeutic role its cancer drug candidate, SOR-C13, can play in helping relieve or prevent severe immune response to the SARS CoV-2 virus.
Soricimed is currently developing SOR-C13, a TRPV6 calcium channel inhibitor, for the treatment of solid-tumour cancers. SOR-C13 is designed to decrease calcium concentrations inside cancer cells to inhibit calcium-dependent cancer cell proliferation and induce the death of tumour cells overexpressing TRPV6.